Isoniazid-monoresistant tuberculosis in France: risk factors, treatment outcomes and adverse events - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue International Journal of Infectious Diseases Année : 2021

Isoniazid-monoresistant tuberculosis in France: risk factors, treatment outcomes and adverse events

Résumé

Objectives: Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared to drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods: A case-control multicentre study was performed to identify risk factors associated with HR-TB and to compare treatment outcomes and safety among HR-TB patients and DS-TB patients. Results: Characteristics of 99 HR-TB diagnosed and treated in university hospitals of Paris, Lille, Caen and Strasbourg were compared to 99 DS-TB's. Female sex (OR = 2.2; 1.0-4.7), birth in the West-Pacific WHO region (OR = 4.6; 1.1-18.7) and resistance to streptomycin (OR = 77.5; 10.1-594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions: Factors associated with HR-TB are not relevant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt the treatment.
Fichier principal
Vignette du fichier
1-s2.0-S1201971221003118-main.pdf (2.4 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03192579 , version 1 (08-04-2021)

Identifiants

Citer

Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, et al.. Isoniazid-monoresistant tuberculosis in France: risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases, 2021, ⟨10.1016/j.ijid.2021.03.093⟩. ⟨hal-03192579⟩
81 Consultations
40 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More